Dube Eric M 4

What Happened

• Eric M. Dube, CEO of Travere Therapeutics (TVTX), had 64,000 performance restricted stock units vest on April 13, 2026 (acquired at $0) and sold all 64,000 shares in open-market/private sales on April 15, 2026 for aggregate proceeds of $2,629,975. Sales broken down: 56,815 shares at a weighted average $41.01 ($2,329,983), 7,165 shares at a weighted average $41.75 ($299,139), and 20 shares at $42.66 ($853).

Key Details

• Filing date: April 15, 2026; Period of report: April 13, 2026.
• Award/Acquisition: 64,000 PSUs vested on April 13, 2026 (acquired at $0) following FDA approval of FILSPARI per footnote.
• Sales: Open-market/private sales on April 15, 2026 totaling 64,000 shares for $2,629,975.
• Plan/Tax: Sales were made under a written 10b5-1 plan adopted June 16, 2025 and include shares sold to cover tax withholding on vesting.
• Price ranges: tranche one weighted avg $41.01 (range $40.51–$41.51); tranche two weighted avg $41.75 (range $41.52–$42.42). Detailed per-price breakdown available on request.
• Shares owned after transaction: Not specified in the filing excerpt provided.
• Filing timeliness: No late filing flag noted in this report.

Context

• This sequence is a common post-vesting transaction: PSUs vested (an award/acquisition event), and the resulting shares were sold (partly to satisfy tax withholding) under a pre-established 10b5-1 plan. Such sales are typically routine and do not, by themselves, indicate managerial views about the company’s stock beyond the mechanics of vesting and tax obligations.